Form 4: CFO Kyle Piskel Exercises Options, Sells ADPT Shares

Adaptive Biotechnologies CFO Kyle Piskel exercised stock options and subsequently sold 4,290 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Kyle Piskel, Chief Financial Officer of Adaptive Biotechnologies Corp (ADPT), executed transactions on January 12, 2026.
• Piskel exercised stock options to acquire 4,290 shares of common stock at an exercise price of $12.14 per share.
• Concurrently, Piskel sold 4,290 shares of common stock at a price of $18.00 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2025.
• Following these transactions, Piskel's direct beneficial ownership of common stock decreased from 220,927 shares to 216,637 shares.
• Piskel retains 4,291 unexercised stock options.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. While an insider sale can be seen negatively, the execution under a 10b5-1 plan mitigates concerns about opportunistic selling. The CFO also realized a profit on the options, which is a positive for executive compensation.

Positives

• The CFO realized a profit of $5.86 per share ($18.00 sale price $12.14 exercise price) on the exercised and sold shares, indicating a positive return on the options.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which suggests the sales were not based on new, non-public information and are part of a planned liquidity strategy.

Negatives

• A reduction in direct beneficial ownership by a key executive, even if planned, could be perceived negatively by some investors as it decreases their direct stake in the company.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the sale as a slight negative due to reduced insider ownership, but the 10b5-1 plan context reduces concern. The profit realized by the CFO is a standard outcome of executive compensation plans.

Key Dates

Recommendation

The filing details a routine insider transaction (option exercise and sale) executed under a pre-arranged 10b5-1 plan. This type of transaction is generally not indicative of new material information and does not provide a strong basis for a change in investment recommendation. The CFO realized a profit, which is a normal outcome of executive compensation. Investors should look to broader company performance and market conditions for investment decisions rather than this specific Form 4.

Keywords

Adaptive Biotechnologies, ADPT, Kyle Piskel, CFO, Form 4, Insider Trading, Stock Options, Share Sale, 10b5-1 Plan, Executive Compensation